Advertisement

Response to letter entitled: Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”

  • Paolo Tarantino
    Correspondence
    Corresponding author: Via Ripamonti 435, 20141, Milan, Italy. Tel.: +2 57489.599; fax: +2 94379 224.
    Affiliations
    Dana-Farber Cancer Institute, Boston, MA, USA

    Harvard Medical School, Boston, MA, USA

    Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
    Search for articles by this author
  • Eleonora Nicolò
    Affiliations
    Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
    Search for articles by this author
  • Giuseppe Curigliano
    Affiliations
    Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
    Search for articles by this author
Published:November 09, 2022DOI:https://doi.org/10.1016/j.ejca.2022.10.008
      We thank Dr. Bravaccini et al. for their thoughtful comments on our work [
      • Tarantino P.
      • Gandini S.
      • Nicolò E.
      • et al.
      Evolution of low HER2 expression between early and advanced-stage breast cancer.
      ] on the evolution of HER2-low expression between early and advanced breast cancer. The authors highlight some important challenges existing in the diagnosis of HER2-low breast cancer, an entity still under definition.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tarantino P.
        • Gandini S.
        • Nicolò E.
        • et al.
        Evolution of low HER2 expression between early and advanced-stage breast cancer.
        Eur J Cancer. Mar. 2022; 163: 35-43https://doi.org/10.1016/j.ejca.2021.12.022
        • Mosele M.F.
        • Lusque A.
        • Dieras V.
        • et al.
        LBA1 - unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial.
        Ann Oncol. 2022; 33: S123-S147
        • Modi S.
        • Jacot W.
        • Yamashita T.
        • et al.
        Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
        N Engl J Med. 2022; 10.1056/NEJMoa2203690https://doi.org/10.1056/NEJMoa2203690
        • Fernandez A.I.
        • Liu M.
        • Bellizzi A.
        • et al.
        Examination of low ERBB2 protein expression in breast cancer tissue.
        JAMA Oncol. Apr 1 2022; 8: 1-4https://doi.org/10.1001/jamaoncol.2021.7239
        • Scott M.
        • Vandenberghe M.E.
        • Scorer P.
        • Boothman A.-M.
        • Barker C.
        Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.
        J Clin Oncol. 2021; 39 (1021-1021)https://doi.org/10.1200/JCO.2021.39.15_suppl.1021
        • Rüschoff J.
        • Friedrich M.
        • Nagelmeier I.
        • et al.
        Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
        Virchows Arch. Aug 16 2022; https://doi.org/10.1007/s00428-022-03378-5
        • Modi S.
        • Park H.
        • Murthy R.K.
        • et al.
        Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study.
        J Clin Oncol. Jun 10 2020; 38: 1887-1896https://doi.org/10.1200/jco.19.02318
        • Gustavson M.
        • Haneder S.
        • Spitzmueller A.
        • et al.
        Abstract PD6-01: novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients.
        Cancer Res. 2021; 81PD6-01-PD6-01https://doi.org/10.1158/1538-7445.Sabcs20-pd6-01
        • Moutafi M.
        • Robbins C.J.
        • Yaghoobi V.
        • et al.
        Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.
        Lab Invest. Oct. 2022; 102: 1101-1108https://doi.org/10.1038/s41374-022-00804-9
        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA A Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660

      Linked Article

      • Evolution of low HER2 expression between early and advanced-stage breast cancer
        European Journal of CancerVol. 163
        • Preview
          Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications.
        • Full-Text
        • PDF
      • Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”
        European Journal of Cancer
        • Preview
          In a phase 3, multicentre, open-label, randomised trial, trastuzumab deruxtecan (TD) was superior to the standard of care trastuzumab emtansine in patients with HER2-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane [1]. Then, a phase 3 trial with HER2-low mBC patients (defined as 1+ and 2+ by immunohistochemistry [IHC] or negative by in situ hybridisation [ISH]) who had received previous lines of chemotherapy was performed [2]. In this trial TD resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
        • Full-Text
        • PDF